Clinical Trial Update: Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers [Phase 1]

View source ↗

Summary

Phase 1 study of the oral STAT3 inhibitor TTI-101 in patients with advanced cancers has completed, with enrollment across multiple tumor types including breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastric Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• TTI-101

Snippet

Sponsor: Tvardi Therapeutics, Incorporated | Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Status: COMPLETED